Valuation: CStone Pharmaceuticals

Market Cap 7.69B 1.15B 1.02B 951M 867M 1.64B 110B 1.65B 11.51B 4.46B 56.37B 4.31B 4.21B 181B P/E 2026 *
-16.7x
P/E 2027 * 4.52x
Enterprise Value 6.71B 1B 890M 830M 757M 1.43B 96.25B 1.44B 10.05B 3.89B 49.2B 3.76B 3.68B 158B EV / Sales 2026 *
15.9x
EV / Sales 2027 * 2.13x
Free-Float
79.65%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: CStone Pharmaceuticals

1 day+6.82%
1 week+19.34%
Current month+3.75%
1 month+2.69%
3 months+13.04%
6 months-32.38%
Current year+16.49%
1 week 0.61
Extreme 0.6104
0.66
1 month 0.55
Extreme 0.554
0.67
Current year 0.45
Extreme 0.4471
1.12
1 year 0.45
Extreme 0.4471
1.12
3 years 0.09
Extreme 0.092
1.35
5 years 0.09
Extreme 0.092
1.35
10 years 0.09
Extreme 0.092
1.98
Manager TitleAgeSince
Chief Executive Officer 62 24/08/2022
Director of Finance/CFO - 17/01/2023
Chief Operating Officer 46 31/07/2016
Director TitleAgeSince
Chairman 55 -
Director/Board Member 62 24/08/2022
Director/Board Member 63 08/07/2021
Change 5-day change 1-year change 3-year change Capi.($)
+6.82%+19.34% - - 1.15B
-0.61%-3.43%+36.07%+115.04% 1,019B
-1.02%-5.60%+35.72%+64.63% 617B
+1.11%-0.58%+12.36%+77.95% 464B
+0.34%-3.01%+61.79%+41.24% 356B
+0.94%-1.80%+21.01%+41.47% 333B
+1.10%-3.13%+11.15%+34.82% 267B
+0.18%-4.85%-6.60%+9.03% 244B
-1.04%-2.79%+35.30%+51.84% 218B
-1.87%-4.10%+28.44%+93.66% 179B
Average +0.51%-3.54%+26.14%+58.85% 410.8B
Weighted average by Cap. -0.20%-3.54%+29.13%+70.69%

Financials

2026 *2027 *
Net sales 423M 63.11M 56.07M 52.34M 47.7M 89.97M 6.07B 90.81M 633M 245M 3.1B 237M 232M 9.95B 1.72B 257M 228M 213M 194M 366M 24.69B 370M 2.58B 999M 12.62B 964M 943M 40.51B
Net income -384M -57.2M -50.83M -47.44M -43.24M -81.55M -5.5B -82.31M -574M -222M -2.81B -215M -210M -9.02B 680M 101M 90.17M 84.16M 76.71M 145M 9.76B 146M 1.02B 395M 4.99B 381M 373M 16.01B
Net Debt -978M -146M -130M -121M -110M -208M -14.02B -210M -1.46B -567M -7.17B -547M -536M -23B -4.02B -600M -533M -498M -453M -855M -57.68B -863M -6.02B -2.33B -29.49B -2.25B -2.2B -94.63B
Logo CStone Pharmaceuticals
CStone Pharmaceuticals is an investment holding company primarily engaged in research and development of therapies for oncology, autoimmune and inflammation, and other key disease areas. Through its subsidiaries, the Company is primarily engaged in the research and development of biopharmaceutical products, the sales of pharmaceutical products, as well as the provision of license of its intellectual property (IP) or commercialization license. The Company’s products primarily include targeted therapies, AYVAKIT (avapritinib), GAVRETO (pralsetinib) and CEJEMLY (sugemalimab). The Company is also engaged in the development and commercialization of immuno-oncology. The Company primarily conducts its businesses in the domestic market and overseas markets, such as Central and Eastern Europe and Switzerland.
Employees
147
Date Price Change
05/10/26 €0.6640 +6.82%
02/10/26 €0.6216 -2.63%
01/10/26 €0.6384 -0.25%
30/09/26 €0.6400 +4.85%
29/09/26 €0.6104 +9.71%
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.832CNY
Average target price
12.36CNY
Spread / Average Target
+155.85%

Quarterly revenue - Rate of surprise